Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
作者信息
Levine Glenn N, D'Amico Anthony V, Berger Peter, Clark Peter E, Eckel Robert H, Keating Nancy L, Milani Richard V, Sagalowsky Arthur I, Smith Matthew R, Zakai Neil
机构信息
Michael E. DeBakey Veteran's Affairs Medical Center, Houston, TX, USA.
出版信息
CA Cancer J Clin. 2010 May-Jun;60(3):194-201. doi: 10.3322/caac.20061. Epub 2010 Feb 2.
Abstract
摘要
相似文献
1
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.前列腺癌的雄激素剥夺治疗与心血管风险：美国心脏协会、美国癌症协会和美国泌尿外科学会的科学咨询意见：得到美国放射肿瘤学会认可
CA Cancer J Clin. 2010 May-Jun;60(3):194-201. doi: 10.3322/caac.20061. Epub 2010 Feb 2.
2
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.前列腺癌中的雄激素剥夺疗法与心血管风险：美国心脏协会、美国癌症协会和美国泌尿外科学会的科学咨询意见：得到美国放射肿瘤学会认可
Circulation. 2010 Feb 16;121(6):833-40. doi: 10.1161/CIRCULATIONAHA.109.192695. Epub 2010 Feb 1.
3
I'm on androgen deprivation therapy (ADT) for prostate cancer. I've heard that it may cause heart problems. Should I be worried?我正在接受前列腺癌的雄激素剥夺疗法（ADT）。我听说这种疗法可能会导致心脏问题。我应该担心吗？
Johns Hopkins Med Lett Health After 50. 2010 May;22(3):8.
4
Androgen deprivation therapy for prostate cancer.前列腺癌的雄激素剥夺治疗
Lancet Oncol. 2017 Oct;18(10):e567. doi: 10.1016/S1470-2045(17)30670-8. Epub 2017 Sep 1.
5
Prostate cancer: cardiovascular mortality and androgen deprivation.前列腺癌：心血管死亡率与雄激素剥夺。
Nat Rev Urol. 2009 May;6(5):252-3. doi: 10.1038/nrurol.2009.75.
6
Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer.促性腺激素释放激素激动剂与前列腺癌男性 2 型糖尿病和心血管疾病风险
Drugs. 2011 Feb 12;71(3):255-61. doi: 10.2165/11588930-000000000-00000.
7
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.雄激素剥夺疗法会增加前列腺癌男性患者的心血管疾病发病率。
Cancer. 2007 Oct 1;110(7):1493-500. doi: 10.1002/cncr.22933.
8
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.雄激素剥夺疗法治疗前列腺癌的心血管效应：当代荟萃分析。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):e55-e64. doi: 10.1161/ATVBAHA.119.313046. Epub 2020 Jan 23.
9
[Cardiovascular risks of androgen deprivation therapy for prostate cancer].[雄激素剥夺疗法治疗前列腺癌的心血管风险]
Urologe A. 2016 May;55(5):627-31. doi: 10.1007/s00120-015-0021-1.
10
Cardiovascular toxicity of androgen deprivation therapy: a new door opens.雄激素剥夺疗法的心血管毒性：一扇新的大门开启了。
J Clin Oncol. 2011 Sep 10;29(26):3500-2. doi: 10.1200/JCO.2011.37.5741. Epub 2011 Aug 15.
引用本文的文献
1
Impact of recreational football in men with prostate cancer undergoing androgen deprivation therapy.娱乐性足球运动对接受雄激素剥夺治疗的前列腺癌男性患者的影响。
BJUI Compass. 2025 Apr 10;6(4):e70008. doi: 10.1002/bco2.70008. eCollection 2025 Apr.
2
[Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review].[雄激素剥夺疗法与前列腺癌患者的心血管疾病发病率：一篇叙述性综述]
Urologie. 2024 Mar;63(3):262-268. doi: 10.1007/s00120-023-02222-1. Epub 2023 Oct 24.
3
Association between genetically proxied HMGCR inhibition and male reproductive health: A Mendelian randomization study.基于遗传关联的 HMGCR 抑制与男性生殖健康的关系：一项孟德尔随机化研究。
Medicine (Baltimore). 2023 Sep 29;102(39):e34690. doi: 10.1097/MD.0000000000034690.
4
An investigation on cervical cancer and human papillomavirus vaccine knowledge, and analysis of influencing factors for choosing domestic or imported 2vHPV vaccine among females in Shenzhen, China.中国深圳女性对宫颈癌和人乳头瘤病毒疫苗知识的调查，以及选择国产或进口 2vHPV 疫苗的影响因素分析。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2225389. doi: 10.1080/21645515.2023.2225389. Epub 2023 Jun 23.
5
Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study.在接受雄激素剥夺疗法治疗前列腺癌的老年男性中获得代谢洞察力（ADT 和代谢研究）：一项纵向、观察性、队列研究方案。
PLoS One. 2023 Feb 10;18(2):e0281508. doi: 10.1371/journal.pone.0281508. eCollection 2023.
6
Knowledge of cervical cancer prevention and treatment, and willingness to receive HPV vaccination among college students in China.中国大学生对宫颈癌预防和治疗的认知，以及对 HPV 疫苗接种的意愿。
BMC Public Health. 2022 Dec 5;22(1):2269. doi: 10.1186/s12889-022-14718-0.
7
Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes.促性腺激素释放激素激动剂治疗前列腺癌与糖尿病男性的心血管疾病风险和高血压的关系。
JAMA Netw Open. 2022 Aug 1;5(8):e2225600. doi: 10.1001/jamanetworkopen.2022.25600.
8
High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort.高剂量率近距离放疗对中高危前列腺癌老年患者的强化治疗：PROSTAGE队列的5年临床结局
Clin Transl Radiat Oncol. 2022 May 21;35:104-109. doi: 10.1016/j.ctro.2022.05.001. eCollection 2022 Jul.
9
Irradiation of localized prostate cancer in the elderly: A systematic literature review.老年局限性前列腺癌的放射治疗：一项系统文献综述。
Clin Transl Radiat Oncol. 2022 Apr 20;35:1-8. doi: 10.1016/j.ctro.2022.04.006. eCollection 2022 Jul.
10
The Role of Testosterone in the Elderly: What Do We Know?睾酮在老年人中的作用：我们了解多少？
Int J Mol Sci. 2022 Mar 24;23(7):3535. doi: 10.3390/ijms23073535.
本文引用的文献
1
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.激素疗法用于患有冠状动脉疾病引起的充血性心力衰竭或心肌梗死的男性前列腺癌患者及死亡率。
JAMA. 2009 Aug 26;302(8):866-73. doi: 10.1001/jama.2009.1137.
2
Duration of androgen suppression in the treatment of prostate cancer.雄激素抑制在前列腺癌治疗中的持续时间。
N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095.
3
Impact of androgen deprivation therapy on cardiovascular disease and diabetes.雄激素剥夺疗法对心血管疾病和糖尿病的影响。
J Clin Oncol. 2009 Jul 20;27(21):3452-8. doi: 10.1200/JCO.2008.20.0923. Epub 2009 Jun 8.
4
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.局部晚期前列腺癌雄激素剥夺治疗后的心血管死亡率：放射治疗肿瘤学组85-31研究
J Clin Oncol. 2009 Jan 1;27(1):92-9. doi: 10.1200/JCO.2007.12.3752. Epub 2008 Dec 1.
5
Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer.新诊断的局限性或复发性前列腺癌接受雄激素抑制治疗男性的死亡原因。
Cancer. 2008 Dec 15;113(12):3290-7. doi: 10.1002/cncr.23970.
6
Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.放射肿瘤学组92 - 02方案的十年随访：局部晚期前列腺癌选择性雄激素剥夺持续时间的III期试验
J Clin Oncol. 2008 May 20;26(15):2497-504. doi: 10.1200/JCO.2007.14.9021. Epub 2008 Apr 14.
7
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.前列腺癌促性腺激素释放激素激动剂治疗期间的代谢变化：与经典代谢综合征的差异。
Cancer. 2008 May 15;112(10):2188-94. doi: 10.1002/cncr.23440.
8
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.前列腺癌联合雄激素阻断治疗期间的脂肪细胞因子、肥胖与胰岛素抵抗
Urology. 2008 Feb;71(2):318-22. doi: 10.1016/j.urology.2007.08.035.
9
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.局部晚期前列腺癌的心血管死亡率与雄激素剥夺治疗持续时间：放射治疗肿瘤学组92-02研究分析
Eur Urol. 2008 Oct;54(4):816-23. doi: 10.1016/j.eururo.2008.01.021. Epub 2008 Jan 15.
10
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.雄激素抑制联合放疗与单纯放疗治疗前列腺癌的随机试验
JAMA. 2008 Jan 23;299(3):289-95. doi: 10.1001/jama.299.3.289.
Zotero 插件